[123I]Iomazenil spect imaging demonstrates significant benzodiazepine receptor reserve in human and nonhuman primate brain

@article{Sybirska1993123IIomazenilSI,
  title={[123I]Iomazenil spect imaging demonstrates significant benzodiazepine receptor reserve in human and nonhuman primate brain},
  author={E. Sybirska and J. Seibyl and J. Bremner and R. Baldwin and M. Al-Tikriti and C. Bradberry and R. Malison and Y. Zea‐Ponce and S. Zoghbi and M. During and A. Goddard and S. W. Woods and P. Hoffer and D. Charney and R. Innis},
  journal={Neuropharmacology},
  year={1993},
  volume={32},
  pages={671-680}
}
SPECT imaging with [123I]iomazenil was used to measure benzodiazepine (BZ) neuroreceptor occupancy of the agonist lorazepam administered at therapeutically relevant doses in humans and supratherapeutic doses in monkeys. Lorazepam at therapeutic doses (0.03 mg/kg, i.v.) administered 90 min after the bolus injection of [123I]iomazenil had no statistically significant effect (P > 0.12) on the washout rates of regional brain activities compared to that in control subjects, although human subjects… Expand
SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder
TLDR
A decrease in measures of benzodiazepine receptor binding was found in left hippocampus and precuneus in panic disorder patients relative to controls and may be related to changes in GABAergic transmission or possible endogenous benzdiazepine compounds. Expand
Quantitation of benzodiazepine receptor binding with PET [11C]iomazenil and SPECT [123I]iomazenil: preliminary results of a direct comparison in healthy human subjects
TLDR
Preliminary findings indicate that PET and SPECT provide comparable results in quantitation of neuroreceptor binding in the human brain. Expand
A proof-of-concept study using [11C]flumazenil PET to demonstrate that pagoclone is a partial agonist
The GABA-ergic system is central to many anxiety disorders and has therefore received much attention. Benzodiazepines are highly effective anxiolytics, leading to their widespread use clinically.Expand
Kinetic modeling of benzodiazepine receptor binding with PET and high specific activity [11C]Iomazenil in healthy human subjects
TLDR
Kinetic modeling using the three compartment model with PET and high specific activity [11C]Iomazenil provides a reliable measure of benzodiazepine receptor binding. Expand
I-123 iomazenil SPECT in patients with mental disorders
TLDR
The rapid washout of I-123 iomazenil from the brains of BZ (+) patients suggests that chronic administration of a clinical dose of Bz affects the binding of I -123 iosine to BZR on the brain. Expand
Benzodiazepine Site Pharmacokinetic/Pharmacodynamic Quantification in Man: Direct Measurement of Drug Occupancy and Effects on the Human Brain In Vivo
TLDR
This first set of experiments which directly measure agonist-induced changes in both pharmacodynamic effects and pharmacokinetic parameters simultaneously and which demonstrate the feasibility of these studies in man are described and are likely to be useful in human psychopharmacology. Expand
GABAA receptor occupancy by subtype selective GABAAα2,3 modulators: PET studies in humans
TLDR
High GABAA receptor occupancy by AZD7325 and AZD6280 could be reached without clear sedative effects and safety and tolerability was determined. Expand
Tiagabine Increases [11C]flumazenil Binding in Cortical Brain Regions in Healthy Control Subjects
TLDR
Preliminary evidence of the ability to measure in vivo, with PET, acute fluctuations in extracellular GABA levels is provided and the first in vivo documentation of a relationship between GABA neurotransmission and EEG γ-band power in humans is provided. Expand
[11C]flumazenil Binding Is Increased in a Dose-Dependent Manner with Tiagabine-Induced Elevations in GABA Levels
TLDR
It is demonstrated that the magnitude of increase in [11C]flumazenil binding observed with PET is directly correlated with tiagabine dose, and the ability to measure in vivo, with PET, acute shifts in extracellular GABA is demonstrated. Expand
Benzodiazepine Receptor Antagonists
TLDR
Flumazenil represents a promising tool for pharmacological investigations of the GABAergic system and for imaging of the benzodiazepine receptor, and as a neuronal marker in epilepsy and cerebral ischaemia. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 19 REFERENCES
Dynamic SPECT imaging after injection of the benzodiazepine receptor ligand [123I]iomazenil in healthy human subjects
TLDR
In summary, [123I]iomazenil is a promising SPECT radioligand for the BZ receptor, with high brain uptake, relatively slow washout of radioactivity, and appropriate regional distribution. Expand
Pharmacokinetics of the SPECT benzodiazepine receptor radioligand [123I]iomazenil in human and non-human primates.
  • S. Zoghbi, R. Baldwin, +7 authors R. Malison
  • Chemistry, Medicine
  • International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology
  • 1992
TLDR
In vitro and in vivo studies showed that [123I]iomazenil established equal concentrations in association with the cellular and plasma component of the blood, indicating that the plasma clearance of [123 mexenil mirrors that of theBlood. Expand
SPECT imaging of the benzodiazepine receptor in non-human primate brain with [123I]Ro 16-0154.
TLDR
SPECT imaging in non-human primates shows 123I-labeled Ro 16-0154 is a promising in vivo SPECT radioligand for the benzodiazepine receptor, with high brain uptake, a stable period of peak radioactivity, appropriate regional distribution, and ability to be displaced by other benzodiazine receptor agents. Expand
SPECT Imaging of the benzodiazepine receptor: Autoradiographic comparison of receptor density and radioligand distribution
TLDR
The ex vivo autoradiograms provided quantitative data from a realistic “biological phantom,” which may be used to assess the accuracy of image reconstruction and to investigate differences between the distribution of an intravenously administered tracer and that of its target in brain tissue. Expand
SPECT imaging of the benzodiazepine receptor: feasibility of in vivo potency measurements from stepwise displacement curves.
TLDR
In conclusion, stepwise displacement by agents administered following the injection of the radioligand 123I-Ro 16-0154 provided a reliable means of measuring the in vivo potencies of BZ receptor agents. Expand
Receptor binding characterization of the benzodiazepine radioligand 125I-Ro16-0154: potential probe for SPECT brain imaging.
TLDR
In vitro results suggest that 123I-labeled Ro16-0154 shows promise as a selective, high affinity SPECT probe of the brain's BZ receptor. Expand
In vitro and in vivo evaluation of iodine-123-Ro 16-0154: a new imaging agent for SPECT investigations of benzodiazepine receptors.
TLDR
The purified 123I-Ro 16-0154 was found to be stable in rat brain preparations and to be metabolized in rat liver preparations, and its pharmacologic properties were comparable to those of flumazenil. Expand
Kinetics of [3H]flunitrazepam binding to membrane-bound benzodiazepine receptors.
TLDR
The kinetics of [3H]flunitrazepam binding to synaptosomal (P2) membranes from rat cerebral cortex was studied and dissociation was faster before equilibrium than after equilibrium had been reached. Expand
GABAergic modulation of benzodiazepine binding site sensitivity
TLDR
GA can modulate the responsiveness of this BZ binding site since the addition of GABA to cortical membranes in vitro results in an increased affinity of the 3H-diazepam binding site for its ligand. Expand
Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor.
TLDR
Although tiagabine antagonized DMCM-induced convulsions, it exhibited neither CGS 9896 or diazepam-like interoceptive effects, nor did it block (or potentiate) pentylenetetrazol-discrimination, thus, GABA uptake inhibition represents a novel rationale for a valproate-like anticonvulsant drug therapy. Expand
...
1
2
...